Pfizer's Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns
Pfizer's Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns
The analyst maintains the Buy rating, with a price target of $36.On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter adjusted EPS of $0.60, down 11% year over year, beating the consensus of $0.46.
辉瑞（Pfizer，NYSE:PFE）周二发布了第二季度调整后的每股收益报告，为0.60美元，同比下降11％，超过了0.46美元的共识预期。
The U.S. drugmaker reported sales of $13.28 billion, up 2% year-over-year (up 3% operationally), beating the consensus of $13.02 billion.
这家美国制药公司报告了132.8亿美元的销售额，同比增长2％（运营上增长3％），超过了130.2亿美元的共识预期。增长主要是由于我们的多个收购产品，主要在市场内的产品以及最近的商业推出的增长贡献，这些增长弥补了Comirnaty预期下降的影响。
Truist Securities sees the strong demand growth as highly encouraging and, at current levels, Pfizer shares are very attractive given the company's diverse portfolio that is gaining momentum, effective cost-cutting initiatives, and a commitment to maintaining or growing an attractive dividend.
Truist证券认为需求增长强劲非常令人鼓舞，考虑到该公司不断增强的多样化投资组合、有效的成本削减措施以及维持或增长可观分红的承诺，在当前水平下，辉瑞股票非常具有吸引力。
The analyst maintains the Buy rating, with a price target of $36.
分析师保持买入评级，并将价格目标定为36美元。
Goldman Sachs notes that Pfizer's performance included noteworthy standouts (Vyndaqel, Nurtec) and evidence that integration of the Seagen acquisition is progressing well.
高盛指出，辉瑞的业绩表现包括值得一提的亮点（Vyndaqel、Nurtec）以及Seagen收购整合顺利的证据。
Goldman Sachs analyst writes, "We were struck by the raised COVID-19 guidance, as we interpret the decision as being underpinned by confidence. Gross margin gains provide reassurance relative to concerns earlier in the year, as gains from cost realignment initiatives are materializing."
高盛分析师写道：“我们对提高的COVID-19指导方针印象深刻，我们认为这一决定是基于信心作出的。毛利率的增长提供了一定的保障，从成本重新调整措施中获得的收益正在实现，相对于年初的担忧变得有所缓解。”
The analyst keeps the Buy rating and raises the price target from $31 to $34.
分析师保持买入评级，并将价格目标从31美元上调至34美元。
BMO Capital Markets writes Pfizer's (Outperform, $36 target) second-quarter earnings highlight the direction of the business as it moves out of the shadow of COVID.
BMO资本市场指出，辉瑞（跑赢市场，目标价36美元）第二季度的盈利强调了业务从COVID阴影中走出的方向。
With COVID revenue stabilizing, base revenue expanding, and clinical development focused on accelerating danuglipron in any way possible, BMO Capital analyst writes that the business's priorities are aligned with shareholders.
随着COVID收入稳定、基础收入扩大，以及临床开发专注于尽可能加速danuglipron的研发，BMO Capital分析师写道，该业务的优先事项与股东的利益保持一致。
Cantor Fitzgerald notes that concerns about Pfizer's patent cliff and downside risk to COVID-19 sales will be offset by Seagen, new product launches, and M&A expected to resume beyond 2025.
康泰菲兹杰拉尔德指出，关于辉瑞的专利悬崖和COVID-19销售下行风险的担忧将被Seagen、新产品推出和2025年后预计恢复的并购所抵消。
Also, along with the strong execution of its cost reduction programs, the updates could drive EPS to $3+ in 2025+ and the stock toward its price target of $45. Maintains the Overweight rating.
此外，伴随着其成本削减计划的强有力的执行，最新信息预计可推动每股收益在2025年达到3美元以上，并推动股价走向45美元的目标。维持超配评级。
Price Action: PFE stock is down 1.85% at $30.81 at last check Wednesday.
价格行动：PFE股票在周三最后一次检查时下跌1.85％，报30.81美元。
Photo via Shutterstock
图片来自shutterstock。
- One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program.
- 一年五次试验失败：FibroGen终止胰腺癌治疗计划。
